PMC:7243768 / 65754-66099 6 Projects
Annnotations
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T487 | 0-345 | Sentence | denotes | Thus, the usage of human recombinant soluble ACE2 (hrsACE2) which exhibited positive results in the phase I and phased II clinical trials to elevate the soluble form of ACE2that competes with the membranous ACE2 for binding with SARS-CoV-2 and inhibits the viral entry and replication can be considered as a therapeutic option to treat COVID-19. |